Abstract Effect of peptides obtained from Phaseolus lunatus L. where biological properties such as antioxidant activity have been found. In addition to improve this beneficial effect, the microencapsulation could be a way to protect the peptides against the environment to which they are exposed. Gums extracted from plant seeds are a potential option such as Guazuma ulmifolia, and its seeds gum exhibits promising properties as coating materials in encapsulation. Two peptide fractions from P. lunatus L. were encapsulated (>10 and <10 kDa) by ionic gelation using mixtures of G. ulmifolia gum and sodium alginate (GUG:SA). A 23 experimental design was used: GUG:SA ratios (A) (70:30 or 30:70); CaCl2 concentrations (B) (0.05 or 0.15 M); and hardening time (C). (10 or 30 min). Multiple variable response analysis with a desirability coefficient identified optimum conditions for each peptide fraction. Better results were obtained for >10 kDa peptide fraction at optimal conditions of A: 70:30, B: 0.05 and C: 10, obtaining irregular beads with a diameter of 5.85 mm2, Bead Encapsulation efficiency 42% and 31 and 42 mM TEAC for ABTS and DPPH respectively. These results shown that GUG:SA mixture is a viable encapsulation system for preserving antioxidant peptide fractions.

Inhibition of angiotensin-converting enzyme I (ACE-I) in vitro and in vivo from peptide fractions by enzymatic hydrolysis of the Vigna unguiculata protein concentrate was evaluated. Hydrolysis was done with Pepsin-Pancreatin and Flavourzima® in two separate systems. The resulting hidrolysates were ultrafiltrated to obtain fractions with different molecular weight. The fractions with better inhibition Flavourzima® were size > 1 kDa (> 1 kDa-F) and < 1 kDa (< 1 kDa-F), with an IC50 of 1222.84 and 1098.6 µg/ml respectively. Pepsin-Pancreatin fraction <1 kDa (<1 kDa-PP) showed the best activity with an IC50 of 402.23 ìg/ml. Hypotensive effect was evaluated in a normotensive model for 4 weeks, 10 mg/kg (weight)/orally, in Wistar rats. < 1 kDa-F decreased systolic: diastolic in 8.61: 14.09% respectively, while in the case of <1 kDa-PP lowed diastolic pressure in 14.15%. Antihypertensive effect was evaluated in induced model for 3 weeks with L-NAME (25 mg/kg (weight)/day). In the next 4 weeks peptide fractions, were administered, noticing >1 kDa-F decreased systolic pressure and diastolic 10.27: 4.92% respectively, while <1 kDa-F decreased diastolic pressure 3.56%. <1 kDa-PP decreased systolic: diastolic in 15.98: 17.12%, respectively.

Se evaluó la inhibición de la enzima convertidora de angiotensina-I (ECA-I) in vitro e in vivo por fracciones peptídicas provenientes de la hidrólisis enzimatica del concentrado proteico de Vigna unguiculata; el cual fue separado en distintos pesos moleculares por ultrafiltración. La hidrolisis se realizó con FlavourzimaR y Pepsina- Pancreatina en dos sistemas separados. Las fracciones obtenidas con FlavourzimaR con mejor inhibición fueron las de tamaño > 1KDa (> 1KDa-F) y < 1KDa (< 1KDa-F), con un IC50 de 1222,84 y 1098,6 µg/ml, respectivamente. Con Pepsina-Pancreatina la fracción < 1KDa (< 1KDa. P-P) presentó la mejor actividad, con un IC50 de 402,23 µg/ml. El efecto hipotensor se evaluó en un modelo normotenso durante cuatro semanas, 10 mg/kg peso/via oral en ratas Wistar. < 1KDa-F disminuyó la presión sistolica: diastólica un 8,61:14,09%, respectivamente; mientras que < 1KDa.P-P disminuyó la presión diastólica un 14,15%. El efecto antihipertensivo se evaluó en un modelo inducido durante tres semanas con L-NAME (25mg/ kg/dia). Durante las siguientes cuatro semanas se administraron las fracciones peptidicas, en donde > 1KDa-F redujo la presión sistólica:diastólica un 10,27:4,92%, respectivamente; mientras que < 1KDa-F disminuyó la presión diastólica un 3,56%. < 1KDa.P-P disminuyó la presión sistólica:diastólica un 15,98:17,12%, respectivamente.